$ALKS

snyderman nancy lynn MD sold $2.2M of ALKS

snyderman nancy lynn MD sold 44,472 shares of Alkermes plc. (ALKS) at $50.35 ($2.24M total) on 2026-08-03.

Original reporting
SEC EDGAR · snyderman nancy lynn MD
Published Aug 3, 2026, 11:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 11:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALKS
Neutral
medium confidence
Mentioned
$ALKS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

A director open-market sale of $2.24M is disclosed, including trade date, share count, price, and remaining holdings; there is no accompanying operational or financial update.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a durable repricing without corroborating fundamental news.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still lacks context on taxes, personal liquidity needs, or whether other insiders made offsetting purchases.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-03 (same day as transaction)

Background

The article is an SEC Form 4 insider transaction disclosure for Alkermes plc.

Company-level read

Ticker impact

$ALKSNeutralMedium confidence
Context

Alkermes director Nancy Lynn Snyderman sold 44,472 shares in an open-market transaction worth about $2.24M, filed on 2026-08-03.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction size, price, and post-sale holdings, but no accompanying company news or guidance change.

Market effects

No clear sector read-through from a single director sale without additional company or industry disclosures.

None indicated.

None indicated.

Counterpoint

The sale may be planned for liquidity or diversification and does not necessarily signal reduced confidence, especially without any other negative company-specific news.

Key entities

  • Alkermes plc

    Subject of the Form 4 insider sale disclosure.

  • Nancy Lynn Snyderman, MD

    Director who sold 44,472 shares at $50.3480 per share.

Related articles

$ALKSMed

Alkermes plc Q2 2026 Earnings Call Summary

Strategic Evolution and Operational Context Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies.

$ALKSMedAI 8/10

Alkermes plc. (ALKS): Results of Operations and Financial Condition

Alkermes plc. (ALKS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2026 Financial Results — Second Quarter Revenues of $496.0 Million — — GAAP Net Income

$ALKSMed

Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy

Alkermes plc reported interim results from a long-term extension study of alixorexton in adults with narcolepsy type 1 and type 2. At week 24, alixorexton showed sustained improvements on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with mean MWT sleep latency about 29 minutes (NT1) and 18 minutes (NT2) and mean ESS about 7.5 (NT1) and 8.9 (NT2). No serious treatment-emergent adverse events were reported.

$ALKSMed

First MS Mobility Drug Gets Green Light From NHS England

NHS England said it will make fampridine (Fampyra), a pill for adults with multiple sclerosis-related walking impairment, routinely available on the NHS after a Clinical Priorities Advisory Group review. NHSE cited trials showing improved walking speed in 43% of patients and about a 25% speed increase, with ~5,000 eligible patients in England in year one. The decision follows a 2022 NICE cost-effectiveness refusal and the expiry of the Fampyra brand patent.